← All trials
NCT04922593
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 13, 2021
- Primary completion
- Mar 12, 2022
- Completion date
- Apr 11, 2022
- First posted
- Jun 10, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 281
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Luye PharmaLead sponsor
- Luye PharmaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.